News >

Shum Sheds Light on Oncogene-Driven NSCLC Treatment Options

Brandon Scalea
Published: Monday, Jan 07, 2019

Elaine Shum, MD

Elaine Shum, MD

Following frontline TKI approvals, researchers are still trying to determine the role of older-generation TKIs in the treatment of patients with oncogene-driven non–small cell lung cancer (NSCLC), as well as ways to overcome acquired resistance to these agents, said Elaine Shum, MD.

State of the Science Summit™ on Advanced Non–Small Cell Lung Cancer, Shum, a medical oncologist at NYU Langone’s Perlmutter Cancer Center, discussed the rapidly evolving treatment options for patients with oncogene-driven NSCLC.

OncLive: What are the updates in frontline options for patients with oncogene-driven NSCLC?

Shum: It has been a very exciting past couple of years in terms of new FDA approvals for drugs in the frontline setting. In my presentation [at the State of the Science SummitTM], I focused on ALK- and EGFR-[targeted therapies], and I also touched on some of the rarer oncogenic drivers.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication